BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MK-3120 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of MK-3120\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07222488-11234@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:MK-3120: Phase 1/2 readout est. (NCT07222488)
DESCRIPTION:MK-3120\, phase 1/2\, Bladder Cancer.\nStudy: A Clinical Study 
 of MK-3120 in People With Bladder Cancer (MK-3120-003)\nEstimated primary 
 completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/mk-3120#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07222488
URL:https://assetmemo.bio/drug/mk-3120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06818643-11234@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280208
DTEND;VALUE=DATE:20280209
SUMMARY:MK-3120: Phase 1/2 readout est. (NCT06818643)
DESCRIPTION:MK-3120\, phase 1/2.\nStudy: A Study to Evaluate the Safety and
  Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-0
 02)\nEstimated primary completion: 8 February 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/mk-3120#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06818643
URL:https://assetmemo.bio/drug/mk-3120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05562830-11234@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290226
DTEND;VALUE=DATE:20290227
SUMMARY:MK-3120: Phase 1/2 readout est. (NCT05562830)
DESCRIPTION:MK-3120\, phase 1/2.\nStudy: A Substudy of Investigational Agen
 ts in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanc
 ed or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)\nEstimated prima
 ry completion: 26 February 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/mk-3120#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05562830
URL:https://assetmemo.bio/drug/mk-3120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232602-11234@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310708
DTEND;VALUE=DATE:20310709
SUMMARY:MK-3120: Phase 1/2 readout est. (NCT07232602)
DESCRIPTION:MK-3120\, phase 1/2\, Bladder Cancer.\nStudy: KEYMAKER-U04 Subs
 tudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin
  and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-
 U04)\nEstimated primary completion: 8 July 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/mk-3120#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07232602
URL:https://assetmemo.bio/drug/mk-3120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
